Abstract

Glioma is one of the most common primary malignancies of the central nervous system, which has aggressive clinical behavior and a poorer prognosis. MicroRNAs (miRs) are a class of small noncoding RNAs that function as mediators of gene expression, which can be sponged by circRNA provided with a closed circular structure. Dysregulations of circular RNAs (circRNAs) and miRs have been implicated in the development and progression of glioma. In the current study, we investigated the role of circular RNA hsa_circ_0076248 in mediating the oncogenesis of glioma by sponging miR‐181a to modulate silent information regulator 1 (SIRT1) expression in vitro and in vivo. The quantitative real‐time polymerase chain reaction results showed that the expression of miR‐181a was significantly decreased in glioma tissues and cell lines compared with normal brain tissues and normal gliocyte, respectively, and the expression of hsa_circ_0076248 and SIRT1 demonstrated the opposite. Bioinformatics analysis identified hsa_circ_0076248 could sponge miR‐181a, and miR‐181a could target the mRNA of SIRT1. Our results verified that downregulating hsa_circ_0076248 or upregulating miR‐181a could depress the proliferation and invasion of glioma in vitro and in vivo. The experiment also showed that downregulating hsa_circ_0076248 or upregulating miR‐181a could remarkably promote the temozolomide chemotherapy sensitivity. Furthermore, Western blot analysis testified that downregulating hsa_circ_0076248 or upregulating miR‐181a could promote the expression of p53 and SIRT1. In summary, our study sheds light on the regulatory mechanism of hsa_circ_0076248 in glioma growth and invasion via sponging miR‐181a, which downregulates the SIRT1 expression and also suggests that hsa_circ_0076248, miR‐181a, and SIRT1 may serve as potential therapeutic targets for glioma.

Highlights

  • Glioblastoma multiforme (GBM) is the most frequent primary tumor in the central nervous system, and patients with malignant glioma have a very poor prognosis.[1,2] Because of the chemotherapy resistance, there is no mature or effective method for GBM therapy.[3,4] Currently, GBM is still being treated by means of radical surgery followed by radiotherapy and chemotherapy.[5-7]

  • silent information regulator 1 (SIRT1) was a target of miR‐181a; the expression levels and the biological function of SIRT1 in human glioma were regulated by miR‐181a

  • Our study put forward to the regulatory mechanism among hsa_circ_0076248, miR‐181a, and SIRT1 in glioma growth and invasion and suggests that hsa_circ_0076248, miR‐181a, and SIRT1 may serve as potential therapeutic targets for glioma in the future

Read more

Summary

| INTRODUCTION

Glioblastoma multiforme (GBM) is the most frequent primary tumor in the central nervous system, and patients with malignant glioma have a very poor prognosis.[1,2] Because of the chemotherapy resistance, there is no mature or effective method for GBM therapy.[3,4] Currently, GBM is still being treated by means of radical surgery followed by radiotherapy and chemotherapy.[5-7]. GBM is still being treated by means of radical surgery followed by radiotherapy and chemotherapy.[5-7] It appears that conventional drugs, such as temozolomide, have therapeutic benefits in prolonging the survival of GBM patients.[8-10]. Recent studies have disclosed various critical roles of circRNAs and miRNAs in cell growth and apoptosis.[15]. Recent studies have shown that mammalian SIRT1 was emerging as a key regulator of cell survival in the face of cellular stresses which otherwise triggered apoptotic pathways.[33,34]. SIRT1 was a target of miR‐181a; the expression levels and the biological function of SIRT1 in human glioma were regulated by miR‐181a. Our study put forward to the regulatory mechanism among hsa_circ_0076248, miR‐181a, and SIRT1 in glioma growth and invasion and suggests that hsa_circ_0076248, miR‐181a, and SIRT1 may serve as potential therapeutic targets for glioma in the future

| MATERIALS AND METHODS
| RESULTS
| DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call